论文部分内容阅读
作者就 Pasteur Merieux Connaught公司生产的百日咳无细胞菌苗DTP(DTaP）在婴儿中的剂量-应答进行了研究。该菌苗以氢氧化铝为佐剂,每0.5ml菌苗含百日咳毒素（PT）和丝状血凝素（FHA）各12.5μg（DTaP-12.5）或25μg(DTaP-25）、破伤风类毒素（TT）10Lf、白喉类毒素（DT）30Lf。以磷酸铝为佐剂的百日咳全细胞菌苗DTP（DTwp）含4个小鼠保护单位的百日咳抗原、5Lf TT和12.5 Lf DT。作者将婴儿随机分成3组,于2、4和6月龄时分别肌肉注射0.5ml上述菌苗,第1和第3针前及第3针后4～8周采集血清样本,置于—20°C保存。
The authors studied the dose-response of infants with the Pasteur Merieux Connaught, Inc., Acellular Pertussis Vaccine DTP (DTaP) in infants. The vaccine was adjuvanted with aluminum hydroxide and contained 12.5 μg (DTaP-12.5) or 25 μg (DTaP-25) of each of pertussis toxin (PT) and filamentous hemagglutinin (FHA) Toxin (TT) 10Lf, Diphtheria toxoid (DT) 30Lf. Pertussis pertussis whole-cell vaccine DTP (DTwp) adjuvanted with aluminum phosphate contained pertussis antigens of 4 mouse protection units, 5 Lf TT and 12.5 Lf DT. The authors randomly assigned infants to three groups, with 0.5 ml of the above vaccine injected intramuscularly at 2,4 and 6 months of age respectively, serum samples taken 4 to 8 weeks before and 1 st and 3 rd stitch, ° C save.